Circulating EM66 is a highly sensitive marker for the diagnosis and follow-up of pheochromocytoma.

Détails

ID Serval
serval:BIB_C471FC01D5AA
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Circulating EM66 is a highly sensitive marker for the diagnosis and follow-up of pheochromocytoma.
Périodique
International journal of cancer. Journal international du cancer
Auteur⸱e⸱s
Guillemot J., Anouar Y., Montero-Hadjadje M., Grouzmann E., Grumolato L., Roshmaninho-Salgado J., Turquier V., Duparc C., Lefebvre H., Plouin P.F., Klein M., Muresan M., Chow B.K., Vaudry H., Yon L.
ISSN
0020-7136
Statut éditorial
Publié
Date de publication
2006
Peer-reviewed
Oui
Volume
118
Numéro
8
Pages
2003-12
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't - Publication Status: ppublish
Résumé
We have previously demonstrated that measurement of tissue concentration of the novel secretogranin II-derived peptide EM66 may help to discriminate between benign and malignant pheochromocytomas. The aim of the present study was to characterize EM66 in plasma and urine of healthy volunteers and pheochromocytoma patients, in order to further evaluate the usefulness of this peptide as a circulating marker for the management of the tumors. HPLC analysis of plasma and urine samples demonstrated that the EM66-immunoreactive material coeluted with the recombinant peptide. In healthy volunteers, plasma and urinary EM66 levels were, respectively, 2.6 (1.9-3.7) ng/ml and 2.9 (1.9-4.6) ng/ml. In patients with pheochromocytoma, plasma EM66 levels were 10-fold higher than those of healthy volunteers (26.9 (7.3-44) ng/ml), and returned to normal values after removal of the tumor. In contrast, urinary EM66 levels were not significantly different from those of healthy volunteers (3.2 (2.2-3.9) ng/ml). Measurement of total or free plasma metanephrines and 24 hr urinary metanephrines in our series of patients revealed that these tests, taken separately, are less sensitive than the EM66 determination. Pheochromocytes in primary culture secreted high levels of EM66, suggesting that the chromaffin tumor was actually responsible for the increased plasma peptide concentrations in the patients. These data indicate that EM66 is secreted in the general circulation and that elevated plasma EM66 levels are correlated with the occurrence of pheochromocytoma. Thus, EM66 is a sensitive plasma marker that should be considered as a complementary tool in the management of pheochromocytoma.
Mots-clé
Adrenal Gland Neoplasms, Adult, Aged, Case-Control Studies, Chromatography, High Pressure Liquid, Chromogranins, Diagnosis, Differential, Female, Humans, Immunoassay, Male, Metanephrine, Middle Aged, Pheochromocytoma, Sensitivity and Specificity, Tumor Markers, Biological
Pubmed
Web of science
Open Access
Oui
Création de la notice
25/01/2008 10:55
Dernière modification de la notice
20/08/2019 15:39
Données d'usage